IPSEN SA SP.ADR 1/4/ EO 1 - Asset Resilience Ratio
IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore total assets of IPSEN SA SP.ADR 1/4/ EO 1 for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how IPSEN SA SP.ADR 1/4/ EO 1's Asset Resilience Ratio has changed over time. See IPSEN SA SP.ADR 1/4/ EO 1 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is IPSEN SA SP.ADR 1/4/ EO 1 worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00 Million | 0.01% |
| Total Liquid Assets | €1.00 Million | 0.01% |
Asset Resilience Insights
- Limited Liquidity: IPSEN SA SP.ADR 1/4/ EO 1 maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IPSEN SA SP.ADR 1/4/ EO 1 Industry Peers by Asset Resilience Ratio
Compare IPSEN SA SP.ADR 1/4/ EO 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for IPSEN SA SP.ADR 1/4/ EO 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€6.94 Billion ≈ $8.11 Billion |
0.00pp |
| 2024-12-31 | 0.02% | €1.10 Million ≈ $1.29 Million |
€6.44 Billion ≈ $7.53 Billion |
-0.15pp |
| 2023-12-31 | 0.17% | €10.60 Million ≈ $12.39 Million |
€6.32 Billion ≈ $7.39 Billion |
-0.38pp |
| 2022-12-31 | 0.55% | €31.00 Million ≈ $36.24 Million |
€5.61 Billion ≈ $6.56 Billion |
-0.30pp |
| 2021-12-31 | 0.85% | €42.40 Million ≈ $49.57 Million |
€4.99 Billion ≈ $5.83 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more